Baseline characteristics of the BCMA CAR-T cohort
| Variable . | All patients N = 156 . | CAR-T product . | P value∗ . | |
|---|---|---|---|---|
| Ide-cel n = 65 . | Cilta-cel n = 91 . | |||
| Age at diagnosis median (IQR) | 55 (48-62) | 54 (48-58) | 55 (48-66) | .51 |
| Age at CAR-T infusion median (IQR) | 62 (55-69) | 61 (53-68) | 63 (56-71) | .19 |
| Secretory type, n (%) | ||||
| Heavy and light chain | 147 (94) | 62 (95) | 85 (93) | .74 |
| Light chain only | 9 (5.8) | 3 (4.6) | 6 (6.6) | |
| Presence of high-risk CG,† n (%) | ||||
| No high-risk CG | 54 (35) | 22 (34) | 32 (35) | .86 |
| High-risk CG | 102 (65) | 43 (66) | 59 (65) | |
| Heavy chain isotype, n (%) | ||||
| IgA | 30 (19) | 13 (20) | 17 (19) | .96 |
| IgG | 89 (58) | 37 (58) | 52 (58) | |
| Light chain only | 35 (23) | 14 (22) | 21 (23) | |
| Year CAR-T infusion, n (%) | ||||
| 2017-2018 | 21 (13) | 18 (28) | 3 (3.3) | <.001 |
| 2019-2021 | 60 (38) | 30 (46) | 30 (33) | |
| 2022-2023 | 75 (48) | 17 (26) | 58 (64) | |
| EMD | ||||
| EMD present | 65 (42) | 23 (35) | 42 (46) | .18 |
| EMD not present | 91 (58) | 42 (65) | 49 (54) | |
| Type of EMD, n (%) | ||||
| Nonparaskeletal | 20 (31) | 4 (17) | 16 (38) | .16 |
| Paraskeletal | 29 (45) | 11 (48) | 18 (43) | |
| Paraskeletal and nonparaskeletal | 16 (25) | 8 (35) | 8 (19) | |
| ISS stage, n (%) | ||||
| Stage I | 55 (44) | 22 (45) | 33 (43) | .73 |
| Stage II | 40 (32) | 17 (35) | 23 (30) | |
| Stage III | 30 (24) | 10 (20) | 20 (26) | |
| Best response after CAR-T, n (%) | ||||
| CR | 99 (64.2) | 36 (55) | 63 (72) | .2 |
| VGPR | 21 (13.6) | 11 (17) | 10 (11) | |
| PR | 17 (11) | 8 (12) | 9 (9.1) | |
| SD/PD | 17 (11) | 10 (15) | 7 (8) | |
| Autologous stem cell transplant, n (%) | 133 (84) | 55 (85) | 78 (84) | .85 |
| Presence of CRS, n (%) | 136 (87.1) | 56 (86) | 80 (88) | .75 |
| Presence of ICANS, n (%) | 19 (12.1) | 7 (11) | 12 (13) | .65 |
| Variable . | All patients N = 156 . | CAR-T product . | P value∗ . | |
|---|---|---|---|---|
| Ide-cel n = 65 . | Cilta-cel n = 91 . | |||
| Age at diagnosis median (IQR) | 55 (48-62) | 54 (48-58) | 55 (48-66) | .51 |
| Age at CAR-T infusion median (IQR) | 62 (55-69) | 61 (53-68) | 63 (56-71) | .19 |
| Secretory type, n (%) | ||||
| Heavy and light chain | 147 (94) | 62 (95) | 85 (93) | .74 |
| Light chain only | 9 (5.8) | 3 (4.6) | 6 (6.6) | |
| Presence of high-risk CG,† n (%) | ||||
| No high-risk CG | 54 (35) | 22 (34) | 32 (35) | .86 |
| High-risk CG | 102 (65) | 43 (66) | 59 (65) | |
| Heavy chain isotype, n (%) | ||||
| IgA | 30 (19) | 13 (20) | 17 (19) | .96 |
| IgG | 89 (58) | 37 (58) | 52 (58) | |
| Light chain only | 35 (23) | 14 (22) | 21 (23) | |
| Year CAR-T infusion, n (%) | ||||
| 2017-2018 | 21 (13) | 18 (28) | 3 (3.3) | <.001 |
| 2019-2021 | 60 (38) | 30 (46) | 30 (33) | |
| 2022-2023 | 75 (48) | 17 (26) | 58 (64) | |
| EMD | ||||
| EMD present | 65 (42) | 23 (35) | 42 (46) | .18 |
| EMD not present | 91 (58) | 42 (65) | 49 (54) | |
| Type of EMD, n (%) | ||||
| Nonparaskeletal | 20 (31) | 4 (17) | 16 (38) | .16 |
| Paraskeletal | 29 (45) | 11 (48) | 18 (43) | |
| Paraskeletal and nonparaskeletal | 16 (25) | 8 (35) | 8 (19) | |
| ISS stage, n (%) | ||||
| Stage I | 55 (44) | 22 (45) | 33 (43) | .73 |
| Stage II | 40 (32) | 17 (35) | 23 (30) | |
| Stage III | 30 (24) | 10 (20) | 20 (26) | |
| Best response after CAR-T, n (%) | ||||
| CR | 99 (64.2) | 36 (55) | 63 (72) | .2 |
| VGPR | 21 (13.6) | 11 (17) | 10 (11) | |
| PR | 17 (11) | 8 (12) | 9 (9.1) | |
| SD/PD | 17 (11) | 10 (15) | 7 (8) | |
| Autologous stem cell transplant, n (%) | 133 (84) | 55 (85) | 78 (84) | .85 |
| Presence of CRS, n (%) | 136 (87.1) | 56 (86) | 80 (88) | .75 |
| Presence of ICANS, n (%) | 19 (12.1) | 7 (11) | 12 (13) | .65 |